Skip to main content Skip to main navigation menu Skip to site footer

The incidence of macular atrophy in patients with long-term use of anti-vascular endothelial growth factor (VEGF) in age-related macular degeneration (AMD): a systematic review and meta-analysis

Abstract

Background: Age-related macular degeneration (AMD) is the chief factor in sightlessness in affluent nations. Visual symptoms at a late stage of AMD are frequently severe and irreversible and might include drastically reduced center vision in both eyes. Patients with nAMD are mostly preserved with anti-vascular endothelial growth factor (VEGF) medications. Chronic anti-VEGF treatment, however, has also been connected to the emergence of macular atrophy (MA). This study aims to determine the prevalence of MA in AMD patients who have been on anti-VEGF medications for a long time.

Methods: The literature research was performed by systematically searching PubMed, Cochrane, ScienceDirect, and Google Scholar using the search terms “macular atrophy”, “Anti-VEGF”, “age-related macular degeneration”, and “trial”. The Review Manager v.5.4 and R statistical software v.3.3 are used in this study.

Results: The study includes 2094 individuals from 7 clinical trial trials. Anti-VEGF therapy had an overall proportion of MA episodes in MDA patients of 0.29 (95% CI 0.24 - 0.34). Between the anti-VEGF and control groups, there is no discernible difference in the risk of MA (OR 1.44; 95% CI 0.34 - 6.04; p=0.39). Additionally, there is no discernible difference between the comparison group and anti-VEGF regarding mean MA area scores (MD 0.03; 95% CI -0.28 - 0.34; p=0.85).

Conclusion: The incidence of MA in long-term anti-VEGF use with other comparators in AMD was not significantly different.

References

  1. Allingham MJ, Loksztejn A, Cousins SW, Mettu PS. Age-related Macular Degeneration, From Clinic to Genes and Back to Patient Management. Vol. 1256, Advances in Experimental Medicine and Biology. 2021. 143–189 p.
  2. Neely DC, Bray KJ, Huisingh CE, Clark ME, McGwin GJ, Owsley C. Prevalence of Undiagnosed Age-Related Macular Degeneration in Primary Eye Care. JAMA Ophthalmol. 2017;135(6):570–5.
  3. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA. 2013;309(19):2005–15.
  4. Chapman NA, Jacobs RJ, Braakhuis AJ. Role of diet and food intake in age-related macular degeneration: a systematic review. Clin Experiment Ophthalmol. 2019;47(1):106–27.
  5. Song D, Liu P, Shang K, Ma Y. Application and mechanism of anti-VEGF drugs in age-related macular degeneration. Front Bioeng Biotechnol. 2022;10:943915.
  6. Owsley C, Huisingh C, Clark ME, Jackson GR, McGwin GJ. Comparison of Visual Function in Older Eyes in the Earliest Stages of Age-related Macular Degeneration to Those in Normal Macular Health. Curr Eye Res. 2016;41(2):266–72.
  7. Thavikulwat AT, Jacobs-El N, Kim JS, Agrón E, Hasan J, Meyerle CB, et al. Evolution of Geographic Atrophy in Participants Treated with Ranibizumab for Neovascular Age-related Macular Degeneration. Ophthalmol Retin. 2017;1(1):34–41.
  8. Abdelfattah NS, Al-Sheikh M, Pitetta S, Mousa A, Sadda SVR, Wykoff CC, et al. Macular Atrophy in Neovascular Age-Related Macular Degeneration with Monthly versus Treat-and-Extend Ranibizumab: Findings from the TREX-AMD Trial. Ophthalmology. 2017;124(2):215–23. Available from: http://dx.doi.org/10.1016/j.ophtha.2016.10.002.
  9. Bailey C, Scott LJ, Rogers CA, Reeves BC, Hamill B, Peto T, et al. Intralesional Macular Atrophy in Anti–Vascular Endothelial Growth Factor Therapy for Age-Related Macular Degeneration in the IVAN Trial. Ophthalmology. 2019;126(1):75–86. Available from: https://doi.org/10.1016/j.ophtha.2018.07.013
  10. Blodi BA, Domalpally A, Corkery E, Osborne A, Blotner S, Grzeschik SM, et al. Prevalence of Macular Atrophy in the MARINA Study of Ranibizumab versus Sham for Neovascular Age-Related Macular Degeneration. Ophthalmol Retin. 2023;7(8):661–71. Available from: https://doi.org/10.1016/j.oret.2023.03.004
  11. Gillies MC, Hunyor AP, Arnold JJ, Guymer RH, Wolf S, Pecheur FL, et al. Macular Atrophy in Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial Comparing Ranibizumab and Aflibercept (RIVAL Study). Ophthalmology. 2020;127(2):198–210. Available from: https://doi.org/10.1016/j.ophtha.2019.08.023
  12. Jaffe GJ, Cameron B, Kardatzke D, Ives J, Barteselli G, Gune S. Prevalence and Progression of Macular Atrophy in Eyes with Neovascular Age-Related Macular Degeneration in the Phase 2 Ladder Trial of the Port Delivery System with Ranibizumab. Ophthalmol Retin. 2022;6(9):786–95. Available from: https://doi.org/10.1016/j.oret.2022.04.006
  13. Sadda SVR, Tuomi LL, Ding B, Fung AE, Hopkins JJ. Macular Atrophy in the HARBOR Study for Neovascular Age-Related Macular Degeneration. Ophthalmology. 2018;125(6):878–86. Available from: https://doi.org/10.1016/j.ophtha.2017.12.026
  14. Spooner KL, Fraser-Bell S, Cozzi M, Staurenghi G, Invernizzi A, Monteduro D, et al. Macular Atrophy Incidence and Progression in Eyes with Neovascular Age-Related Macular Degeneration Treated with Vascular Endothelial Growth Factor Inhibitors Using a Treat-and-Extend or a Pro Re Nata Regimen: Four-Year Results of the MANEX Study. Ophthalmology. 2020;127(12):1663–73. Available from: https://doi.org/10.1016/j.ophtha.2020.06.019
  15. Styliani B, Blavakis E, Smoustopoulos G, Bontzos G, Stavrakakis A, Chlouverakis G, et al. Progression of macular atrophy in patients receiving long-term anti-VEGF therapy for age-related macular degeneration; Real Life Data. Invest Ophthalmol Vis Sci. 2021;62(8):289.
  16. Cho HJ, Kim K, Lim SH, Kang DH, Kim JW. Retinal pigment epithelial atrophy after anti-vascular endothelial growth factor therapy for polypoidal choroidal vasculopathy. Br J Ophthalmol. 2020;104(10):1443–7.
  17. Foss A, Rotsos T, Empeslidis T, Chong V. Development of Macular Atrophy in Patients with Wet Age-Related Macular Degeneration Receiving Anti-VEGF treatment. Ophthalmologica. 2022;245(3):204–17.
  18. Mantel I, Dirani A, Zola M, Parvin P, De Massougnes S, Bergin C. Macular Atrophy Incidence in Anti- Vascular Endothelial Growth Factor–Treated Neovascular Age-Related Macular Degeneration: Risk Factor Evaluation for Individualized Treatment Need of Ranibizumab or Aflibercept According to an Observe-and-Plan Regimen. Retina. 2019;39(5):906–17.
  19. Vyas A, Raman S, Surya J, Sen S, Raman R. The Need for Artificial Intelligence Based Risk Factor Analysis for Age-Related Macular Degeneration: A Review. Diagnostics. 2023;13(1):1–21.
  20. Sato T, Enoki T, Karasawa Y, Someya H, Taguchi M, Harimoto K, et al. Inflammatory Factors of Macular Atrophy in Eyes With Neovascular Age-Related Macular Degeneration Treated With Aflibercept. Front Immunol. 2021;12(10):1–17.

How to Cite

Dharmaputri P, N. Y. S., Saraswati, P. P. T. ., Suryathi, N. M. A. ., & Andayani, A. . (2024). The incidence of macular atrophy in patients with long-term use of anti-vascular endothelial growth factor (VEGF) in age-related macular degeneration (AMD): a systematic review and meta-analysis. Intisari Sains Medis, 15(1), 420–425. https://doi.org/10.15562/ism.v15i1.1998

HTML
0

Total
0

Share

Search Panel

Nyoman Yuni Suryani Dharmaputri P
Google Scholar
Pubmed
ISM Journal


Putu Putri Titamia Saraswati
Google Scholar
Pubmed
ISM Journal


Ni Made Ari Suryathi
Google Scholar
Pubmed
ISM Journal


Ari Andayani
Google Scholar
Pubmed
ISM Journal